How many 8-K filings has Propanc Biopharma, Inc. filed?

Propanc Biopharma, Inc. (PPCB) has 27 8-K (Current Event Report) filings on record, spanning Mar 2024 to Nov 2025.

What is a 8-K filing?

A 8-K is an SEC filing known as "Current Event Report." Filed to announce significant events or material changes such as acquisitions, executive departures, earnings announcements, or bankruptcy filings.

Where can I read Propanc Biopharma, Inc. 8-K filings in plain English?

ReadTheFiling provides AI-powered plain-English summaries of all Propanc Biopharma, Inc. 8-K filings, including risk assessment, sentiment analysis, and key financial figures.

Propanc Biopharma, Inc. (PPCB) — 8-K Filings

All 8-K filings from Propanc Biopharma, Inc.. Browse 27 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (27)

Propanc Biopharma Files 8-K on Equity Sales & Amendments — Nov 10, 2025 Risk: medium
Propanc Biopharma, Inc. filed an 8-K on November 10, 2025, reporting on events that occurred on November 4, 2025. The filing includes information on unregistere
Propanc Biopharma Enters Material Definitive Agreement — Oct 14, 2025 Risk: medium
Propanc Biopharma, Inc. entered into a material definitive agreement on October 7, 2025. The company, incorporated in Delaware with its principal executive offi
Propanc Biopharma Reports Key Corporate Events — Aug 19, 2025 Risk: medium
Propanc Biopharma, Inc. filed an 8-K on August 19, 2025, reporting on several key events that occurred on August 14, 2025. These include entering into a materia
Propanc Biopharma Reports Officer and Director Changes — Aug 13, 2025 Risk: medium
Propanc Biopharma, Inc. filed an 8-K on August 13, 2025, reporting events as of July 31, 2025. The filing indicates changes related to the departure of director
Propanc Biopharma Files 8-K: Agreements & Equity Sales — Jul 30, 2025 Risk: medium
On July 25, 2025, Propanc Biopharma, Inc. entered into a material definitive agreement and created a direct financial obligation. The company also reported unre
Propanc Biopharma Reports Material Agreement & Equity Sales — Jul 22, 2025 Risk: medium
On July 18, 2025, Propanc Biopharma, Inc. entered into a material definitive agreement, likely related to its financial obligations. The company also reported o
Propanc Biopharma Files 8-K: Material Agreement, Debt, Equity Sales — Jun 27, 2025 Risk: medium
On June 20, 2025, Propanc Biopharma, Inc. entered into a material definitive agreement. The company also reported the creation of a direct financial obligation
Propanc Biopharma Files 8-K: Material Agreement, Debt, Equity Sales — Jun 18, 2025 Risk: medium
On June 12, 2025, Propanc Biopharma, Inc. entered into a material definitive agreement. The company also reported the creation of a direct financial obligation
Propanc Biopharma Files 8-K: Material Agreement & Equity Sales — Jun 2, 2025 Risk: medium
On May 7, 2025, Propanc Biopharma, Inc. entered into a material definitive agreement and created a direct financial obligation. The company also reported unregi
Propanc Biopharma Reports Definitive Agreement and Equity Sales — May 8, 2025 Risk: medium
On May 7, 2025, Propanc Biopharma, Inc. entered into a material definitive agreement. The company also reported the creation of a direct financial obligation an
Propanc Biopharma Files 8-K on Agreements and Equity Sales — Apr 21, 2025 Risk: medium
Propanc Biopharma, Inc. filed an 8-K on March 31, 2025, reporting on the entry into a material definitive agreement and the creation of a direct financial oblig
Propanc Biopharma Files 8-K: Material Agreement & Equity Sales — Mar 18, 2025 Risk: medium
Propanc Biopharma, Inc. entered into a material definitive agreement on March 14, 2025. The company also created a direct financial obligation and reported unre
Propanc Biopharma Files 8-K: Material Agreement & Equity Sales — Feb 12, 2025 Risk: medium
Propanc Biopharma, Inc. entered into a material definitive agreement on February 6, 2025. The company also created a direct financial obligation and reported un
Propanc Biopharma Files 8-K: Agreements, Obligations, Equity Sales — Dec 20, 2024 Risk: medium
On December 16, 2024, Propanc Biopharma, Inc. entered into a material definitive agreement. The company also incurred a direct financial obligation or an obliga
Propanc Biopharma Enters Material Definitive Agreement — Dec 6, 2024 Risk: medium
On December 3, 2024, Propanc Biopharma, Inc. entered into a material definitive agreement. This agreement also created a direct financial obligation or an oblig
Propanc Biopharma Enters Material Agreement, Sells Equity — Sep 27, 2024 Risk: medium
Propanc Biopharma, Inc. announced on September 23, 2024, the entry into a material definitive agreement. This filing also details the creation of a direct finan
Propanc Biopharma Enters Material Definitive Agreement — Aug 30, 2024 Risk: medium
Propanc Biopharma, Inc. entered into a material definitive agreement on August 26, 2024. This agreement creates a direct financial obligation for the registrant
Propanc Biopharma Files 8-K: Material Agreement, Debt, Equity Sales — Aug 15, 2024 Risk: medium
Propanc Biopharma, Inc. announced on August 9, 2024, that it entered into a material definitive agreement. The company also disclosed the creation of a direct f
Propanc Biopharma Files 8-K on Agreements and Equity Sales — Aug 7, 2024 Risk: medium
Propanc Biopharma, Inc. filed an 8-K on August 7, 2024, reporting a material definitive agreement and the creation of a direct financial obligation. The filing
Propanc Biopharma Files 8-K on Agreements and Equity Sales — Jul 2, 2024 Risk: medium
Propanc Biopharma, Inc. entered into a material definitive agreement on June 26, 2024, related to a direct financial obligation. The company also reported on un
Propanc Biopharma Files 8-K: Material Agreement & Equity Sales — Jun 21, 2024 Risk: medium
On June 17, 2024, Propanc Biopharma, Inc. entered into a material definitive agreement, creating a direct financial obligation. The company also reported on unr
Propanc Biopharma Files 8-K on Agreements and Equity Sales — Jun 12, 2024 Risk: medium
On June 3, 2024, Propanc Biopharma, Inc. entered into a material definitive agreement related to its financial obligations. The company also reported on the cre
Propanc Biopharma Files 8-K: Material Agreement & Equity Sales — Jun 5, 2024 Risk: medium
Propanc Biopharma, Inc. entered into a material definitive agreement on May 31, 2024. The company also created a direct financial obligation and reported unregi
Propanc Biopharma Enters Material Definitive Agreement — May 16, 2024 Risk: medium
On May 10, 2024, Propanc Biopharma, Inc. entered into a material definitive agreement. This filing also indicates the creation of a direct financial obligation
Propanc Biopharma Files 8-K: Material Agreement & Equity Sales — Apr 22, 2024 Risk: medium
On April 16, 2024, Propanc Biopharma, Inc. entered into a material definitive agreement. The company also reported the creation of a direct financial obligation
Propanc Biopharma Files 8-K — Apr 10, 2024 Risk: low
Propanc Biopharma, Inc. filed an 8-K on April 10, 2024, reporting other events and financial statements. The company, incorporated in Delaware, has its principa
Propanc Biopharma Files 8-K: Material Agreement, Debt, Equity Sales — Mar 11, 2024 Risk: medium
Propanc Biopharma, Inc. announced on March 5, 2024, that it entered into a material definitive agreement. The company also reported the creation of a direct fin

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX